[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651822":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":38,"locations":47,"responsibleParty":70,"collaborators":66,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":66,"eligibilityCriteria":78,"healthyVolunteers":75,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":66,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":50,"whyStopped":66,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"King Edward Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"NAC Group","EXPERIMENTAL","Oral or nasogastric N-acetylcysteine, 140 mg\u002Fkg every 4 hours for the first 16 hours, then every 6-8 hours, continued for 3 days, plus standard supportive care.\n\nIntervention: Drug: N-acetylcysteine",[13],"Drug: N Acetyl Cysteine",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Group","ACTIVE_COMPARATOR","Standard supportive care protocol for acute liver failure (glucose control, antimicrobials, PPIs, fluid\u002Felectrolyte management, antiencephalopathy measures, FFP as needed). Intervention: Other: Standard Supportive Care",[19],"Other: Standard supportive care",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","N Acetyl Cysteine","Oral or nasogastric N-acetylcysteine administered at 140 mg\u002Fkg every 4 hours for the first 16 hours, followed by 140 mg\u002Fkg every 6-8 hours, continued for a total duration of 3 days, given in addition to standard supportive care.",[9],[27],"NAC",{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Standard supportive care","Standard supportive care protocol for acute liver failure (glucose control, antimicrobials, PPIs, fluid\u002Felectrolyte management, anti-encephalopathy measures, FFP as needed).",[15],[33],"Supportive care protocol for liver failure",[35],{"name":36,"affiliation":5,"role":37},"Somia Iqtadar, FCPS","PRINCIPAL_INVESTIGATOR",[39,44],{"name":36,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","+92 42 99211129","331","somia.iqtadar@gmail.com",{"name":45,"role":40,"phone":41,"phoneExt":42,"email":46},"Zaeem Ahmad, MBBS","zaeem.ahmad344@gmail.com",[48],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"King Edward Medical University\u002FMayo Hospital Lahore","RECRUITING","Lahore","Punjab Province","54000","Pakistan","PK",{"type":57,"coordinates":58},"Point",[59,60],74.35071,31.558,{"lat":60,"lon":59},[63,65,67,68],{"name":64,"role":40,"phone":41,"phoneExt":42,"email":46},"Israr Toor, FCPS",{"name":66,"role":40,"phone":66,"phoneExt":66,"email":46},null,{"name":45,"role":37,"phone":66,"phoneExt":66,"email":66},{"name":36,"role":69,"phone":66,"phoneExt":66,"email":66},"SUB_INVESTIGATOR",{"type":37,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":66,"oldOrganization":66},"somia iqtadar","Associate Professor","100651822","role-of-n-acetylcysteine-in-non-acetaminophen-induced-liver-failure-100651822",false,"NCT07765823","Role of N-Acetylcysteine in Non-Acetaminophen-Induced Liver Failure","Inclusion Criteria:\n\n* Male or female, aged 18-60 years\n* Diagnosed with non-acetaminophen- induced acute hepatic failure (per operational definition\u002FEASL criteria)\n* Etiology other than acetaminophen overdose (viral hepatitis HAV\u002FHBV\u002FHEV, non-acetaminophen drug-induced liver injury, or idiopathic)\n* No NAC treatment received for current episode prior to enrollment\n\nExclusion Criteria:\n\n* History of chronic liver disease or cirrhosis\n* Prior severe cardiac, renal, neurological, or infectious disease that could confound outcomes\n* Prior liver transplant or current transplant candidacy\n* Known allergy\u002Fcontraindication to NAC\n* Pregnant women.","ALL","18 Years","60 Years",{"count":83,"type":84},62,"ESTIMATED","INTERVENTIONAL",[87],"NA","This randomized controlled trial evaluates whether oral N-acetylcysteine (NAC), given alongside standard supportive care, improves survival and reduces mortality in patients with non-acetaminophen-induced acute liver failure (ALF), compared to supportive care alone. Secondary objectives are to assess NAC's effect on length of hospital stay and improvement in liver function tests. Sixty-two adult patients (18-60 years) will be randomized 1:1 to NAC or control, with outcomes assessed at 28 days (survival\u002Fmortality) and day 4 (liver function tests).",[90],"Acute Liver Failure",[92,93,94,95,96],"hepatic failure","acute liver failure","acetylcysteine","randomized controlled trial","supportive care","2026-08-16",{"date":99,"type":100},"2026-08-19","ACTUAL",{"date":102,"type":100},"2026-07-16",{"date":104,"type":84},"2026-10-17",{"name":5,"class":6},1]